Celgene Corporation (CELG) : On Wednesday, The money flowed into the Celgene Corporation (CELG) stock with an uptick to downtick ratio was recorded at 1.16. Transactions worth $117.56 million were done on upticks, confirming the buying interest in the stock. The outflow of money on downticks stood at $100.96 million. The total money flow into the stock was $16.6 million. The block trades reveal a bullish bias with an up-down ratio of 2.32. The investors are using every small weakness in the stock to accumulate it, as can be seen in the $30.47 million of block transactions on upticks. The value of block trades on downticks was $13.14 million, indicating lower selling interest. The total money flow in block trades was $17.33 million. In terms of price action, Celgene Corporation (CELG) traded down $1.57 during the session at $105.83. Compared to the previous days closing, the stock was down only by -1.46%. For the week, the stock is -3.29%, over previous weeks closing.
Celgene Corporation has lost 3.42% in the last five trading days and dropped 1.96% in the last 4 weeks. Celgene Corporation is up 7.1% in the last 3-month period. Year-to-Date the stock performance stands at -11.63%.
Celgene Corporation (CELG) : The consensus on Celgene Corporation (CELG) based on 17 analyst recommendation on the company stock is 1.35, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 14 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 3 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.
Celgene Corporation (NASDAQ:CELG): stock was range-bound between the intraday low of $105.45 and the intraday high of $107.62 after having opened at $107.62 on Wednesdays session. The stock finally closed in the red at $107.62, a loss of -1.46%. The stock remained in the red for the whole trading day. The total traded volume was 4,713,821 shares. The stock failed to cross $107.62 in Wednesdays trading. The stocks closing price on Thursday was $107.4.
Celgene Corporation (Celgene), together with its subsidiaries, is an integrated biopharmaceutical company engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Companys primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE, POMALYST/IMNOVID, VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States), OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies, targeting areas, including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies.